[Retracted] Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets

Figure 3

Targeting performance evaluation of cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles. (a) The fluorescence signal of nanoparticles detected by laser confocal microscopy at 0.5, 2 h, 4 h, and 8 h in vitro. (b) The T1-MRI signal was enhanced as the concentration of the original nanomaterials increased. (c) Flow cytometry analysis was utilized to detect the phagocytosis affected by nanoparticles. (d) ICP–AES was utilized to detect the enrichment of cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles in the arterial plaque. Data are shown as the , vs. platelet@MnO/MSN@PPARα/LXRα. for (a) and (c); for (b) and (d).

(a)

(b)

(c)

(d)